THOR up +0.91% percent Today $THOR High is at 30.84 and the Low 30.00 with current volume of 526,564.
Recent News posted below.
Thoratec Corp THOR other info.
http://investorshangout.com/Thoratec-Corp-THOR-55634/
THOR Thoratec Corp Recent Headline News
Upgrade Alert for Thoratec (THOR)
Comtex SmarTrend(R) - Mon Nov 17, 7:58AM CST
Thoratec (NASDAQ:THOR) was upgraded from Market Perform to Outperform at Wells Fargo today. The stock closed yesterday at $29.80 on volume of 2.0 million shares, above average daily volume of 836,000. In the past 52 weeks, shares of Thoratec have traded between a low of $22.50 and a high of $43.50 and closed yesterday at $29.80, which is 32% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.2% while the 200-day MA has slid 0.5%.
THOR: 29.30 (-0.50)
Update: Thoratec Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 15, 7:28AM CST
THOR: 29.30 (-0.50)
Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.83 (+0.58), EW: 125.99 (+1.49), THOR: 29.30 (-0.50), ANGO: 16.90 (+0.08)
Downtrend Call Working As Thoratec Stock Falls 16.3% (THOR)
Comtex SmarTrend(R) - Wed Nov 12, 10:02AM CST
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 4 months, Thoratec has returned 16.33% as of today's recent price of $27.72.
THOR: 29.30 (-0.50)
Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.83 (+0.58), CYNO: 27.69 (+0.31), THOR: 29.30 (-0.50), ANGO: 16.90 (+0.08)
Thoratec Announces Presentations At Investor Conferences For November 2014
PR Newswire - Thu Nov 06, 8:15AM CST
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.
THOR: 29.30 (-0.50)
Thoratec's (THOR) CEO Keith Grossman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 10:32PM CST
THOR: 29.30 (-0.50)
Thoratec misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 5:21PM CST
PLEASANTON, Calif. (AP) _ Thoratec Corp. (THOR) on Wednesday reported net income of $2.9 million in its third quarter.
THOR: 29.30 (-0.50)
Thoratec misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:52PM CST
THOR: 29.30 (-0.50)
Thoratec (THOR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
THOR: 29.30 (-0.50)
Thoratec® Reports Third Quarter 2014 Results
PR Newswire - Wed Nov 05, 3:02PM CST
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the third quarter of 2014.
THOR: 29.30 (-0.50)
Thoratec Shares Down 18.1% Since SmarTrend's Sell Call (THOR)
Comtex SmarTrend(R) - Wed Nov 05, 9:24AM CST
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 4 months, Thoratec has returned 18.07% as of today's recent price of $27.15.
THOR: 29.30 (-0.50)
Downtrend Call Working As Thoratec Stock Falls 20.7% (THOR)
Comtex SmarTrend(R) - Tue Oct 28, 5:17PM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 20.68% as of today's recent price of $26.28.
THOR: 29.30 (-0.50)
Thoratec (THOR) Stock Sinks on Analyst Downgrade Today
at The Street - Tue Oct 28, 8:38AM CDT
Thoratec (THOR) stock is lower today after the company had its rating cut to 'equal weight' from 'overweight' at Barclays.
THOR: 29.30 (-0.50)
Global Left Ventricular Assist Device (LVAD) Market Report: 2014 Edition
M2 - Fri Oct 24, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jpdw7l/global_left) has announced the addition of the "Global Left Ventricular Assist Device (LVAD) Market Report: 2014 Edition" report to their offering. The LVAD companies compete with each other on the basis of substantially greater or broader financial base of the company, product development, sales and marketing resources and experience. Products in this market mainly compete on the basis of product safety, compliance with the prevailing regulations as well as efficiency as a treatment for congestive heart failure as compared to other devices and other treatments. Furthermore, the high prevalence of heart failure coupled with the limited availability of heart donors, aging baby-boomer population, and new and improved technologies is likely to contribute to the market growth. The key factors driving growth of the global LVAD industry include rising diabetic population, increasingly ageing population with heart disorder and escalating healthcare expenditure. Also, growing bridge-to-transplant, which help patients to survive until a donor heart becomes available for transplant, is a major driver for LVAD market. Some of the noteworthy developments of this industry include reimbursement trends and expansion in the number of LVAD centers. However, the growth of respective industry is hindered by the barrier for destination therapy adoption and safety issues. This report offers a comprehensive analysis of the worldwide LVAD market, along with an in-depth study of the US market. The competition in the respective market is intense with two large players viz Thoratec Corporation and Heartware Holdings, among others. The competitive landscape of the global LVAD markets, along with the company profiles of the leading players are also discussed in detail. Key Topics Covered: 1. Overview 2. LVAD Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abiomed, Inc. - Heartware International Inc. - Thoratec Corporation For more information visit http://www.researchandmarkets.com/research/jp...lobal_left
THOR: 29.30 (-0.50)
Thoratec Has Returned 19.6% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Tue Oct 21, 11:14AM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 19.62% as of today's recent price of $26.63.
THOR: 29.30 (-0.50)
Global LVAD Market Report 2014 Edition Now Available at MarketReportsOnline.com
PRWeb - Mon Oct 20, 8:31AM CDT
LVAD, Left Ventricular Assist Device, is a mechanical device that circulates blood throughout the body when the heart is too weak to pump blood on its own. They are used in bridge-to-transplantation (BTT), destination therapy (DT) and bridge to recovery. With the existing conventional therapies and other invasive therapies that provide only symptomatic benefits to patients, LVAD is a key potential area of focus for researchers and various manufacturers at present. The cost-effectiveness and increased insurance reimbursement conditions are likely to increase the demand for LVADs in the future.
THOR: 29.30 (-0.50)
Thoratec Schedules Third Quarter Conference Call, Webcast
PR Newswire - Wed Oct 15, 8:00AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter of fiscal year 2014 on Wednesday, November 5.
THOR: 29.30 (-0.50)
Shares of THOR Down 20.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 14, 9:59AM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 20.34% as of today's recent price of $26.39.
THOR: 29.30 (-0.50)
Shares of THOR Down 19.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 07, 9:23AM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 19.17% as of today's recent price of $26.78.
THOR: 29.30 (-0.50)
Recent News posted below.
Thoratec Corp THOR other info.
http://investorshangout.com/Thoratec-Corp-THOR-55634/
THOR Thoratec Corp Recent Headline News
Upgrade Alert for Thoratec (THOR)
Comtex SmarTrend(R) - Mon Nov 17, 7:58AM CST
Thoratec (NASDAQ:THOR) was upgraded from Market Perform to Outperform at Wells Fargo today. The stock closed yesterday at $29.80 on volume of 2.0 million shares, above average daily volume of 836,000. In the past 52 weeks, shares of Thoratec have traded between a low of $22.50 and a high of $43.50 and closed yesterday at $29.80, which is 32% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.2% while the 200-day MA has slid 0.5%.
THOR: 29.30 (-0.50)
Update: Thoratec Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 15, 7:28AM CST
THOR: 29.30 (-0.50)
Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.83 (+0.58), EW: 125.99 (+1.49), THOR: 29.30 (-0.50), ANGO: 16.90 (+0.08)
Downtrend Call Working As Thoratec Stock Falls 16.3% (THOR)
Comtex SmarTrend(R) - Wed Nov 12, 10:02AM CST
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 4 months, Thoratec has returned 16.33% as of today's recent price of $27.72.
THOR: 29.30 (-0.50)
Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.83 (+0.58), CYNO: 27.69 (+0.31), THOR: 29.30 (-0.50), ANGO: 16.90 (+0.08)
Thoratec Announces Presentations At Investor Conferences For November 2014
PR Newswire - Thu Nov 06, 8:15AM CST
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.
THOR: 29.30 (-0.50)
Thoratec's (THOR) CEO Keith Grossman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 10:32PM CST
THOR: 29.30 (-0.50)
Thoratec misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 5:21PM CST
PLEASANTON, Calif. (AP) _ Thoratec Corp. (THOR) on Wednesday reported net income of $2.9 million in its third quarter.
THOR: 29.30 (-0.50)
Thoratec misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:52PM CST
THOR: 29.30 (-0.50)
Thoratec (THOR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
THOR: 29.30 (-0.50)
Thoratec® Reports Third Quarter 2014 Results
PR Newswire - Wed Nov 05, 3:02PM CST
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the third quarter of 2014.
THOR: 29.30 (-0.50)
Thoratec Shares Down 18.1% Since SmarTrend's Sell Call (THOR)
Comtex SmarTrend(R) - Wed Nov 05, 9:24AM CST
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 4 months, Thoratec has returned 18.07% as of today's recent price of $27.15.
THOR: 29.30 (-0.50)
Downtrend Call Working As Thoratec Stock Falls 20.7% (THOR)
Comtex SmarTrend(R) - Tue Oct 28, 5:17PM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 20.68% as of today's recent price of $26.28.
THOR: 29.30 (-0.50)
Thoratec (THOR) Stock Sinks on Analyst Downgrade Today
at The Street - Tue Oct 28, 8:38AM CDT
Thoratec (THOR) stock is lower today after the company had its rating cut to 'equal weight' from 'overweight' at Barclays.
THOR: 29.30 (-0.50)
Global Left Ventricular Assist Device (LVAD) Market Report: 2014 Edition
M2 - Fri Oct 24, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jpdw7l/global_left) has announced the addition of the "Global Left Ventricular Assist Device (LVAD) Market Report: 2014 Edition" report to their offering. The LVAD companies compete with each other on the basis of substantially greater or broader financial base of the company, product development, sales and marketing resources and experience. Products in this market mainly compete on the basis of product safety, compliance with the prevailing regulations as well as efficiency as a treatment for congestive heart failure as compared to other devices and other treatments. Furthermore, the high prevalence of heart failure coupled with the limited availability of heart donors, aging baby-boomer population, and new and improved technologies is likely to contribute to the market growth. The key factors driving growth of the global LVAD industry include rising diabetic population, increasingly ageing population with heart disorder and escalating healthcare expenditure. Also, growing bridge-to-transplant, which help patients to survive until a donor heart becomes available for transplant, is a major driver for LVAD market. Some of the noteworthy developments of this industry include reimbursement trends and expansion in the number of LVAD centers. However, the growth of respective industry is hindered by the barrier for destination therapy adoption and safety issues. This report offers a comprehensive analysis of the worldwide LVAD market, along with an in-depth study of the US market. The competition in the respective market is intense with two large players viz Thoratec Corporation and Heartware Holdings, among others. The competitive landscape of the global LVAD markets, along with the company profiles of the leading players are also discussed in detail. Key Topics Covered: 1. Overview 2. LVAD Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abiomed, Inc. - Heartware International Inc. - Thoratec Corporation For more information visit http://www.researchandmarkets.com/research/jp...lobal_left
THOR: 29.30 (-0.50)
Thoratec Has Returned 19.6% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Tue Oct 21, 11:14AM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 19.62% as of today's recent price of $26.63.
THOR: 29.30 (-0.50)
Global LVAD Market Report 2014 Edition Now Available at MarketReportsOnline.com
PRWeb - Mon Oct 20, 8:31AM CDT
LVAD, Left Ventricular Assist Device, is a mechanical device that circulates blood throughout the body when the heart is too weak to pump blood on its own. They are used in bridge-to-transplantation (BTT), destination therapy (DT) and bridge to recovery. With the existing conventional therapies and other invasive therapies that provide only symptomatic benefits to patients, LVAD is a key potential area of focus for researchers and various manufacturers at present. The cost-effectiveness and increased insurance reimbursement conditions are likely to increase the demand for LVADs in the future.
THOR: 29.30 (-0.50)
Thoratec Schedules Third Quarter Conference Call, Webcast
PR Newswire - Wed Oct 15, 8:00AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter of fiscal year 2014 on Wednesday, November 5.
THOR: 29.30 (-0.50)
Shares of THOR Down 20.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 14, 9:59AM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 20.34% as of today's recent price of $26.39.
THOR: 29.30 (-0.50)
Shares of THOR Down 19.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 07, 9:23AM CDT
SmarTrend identified a Downtrend for Thoratec (NASDAQ:THOR) on July 16th, 2014 at $33.13. In approximately 3 months, Thoratec has returned 19.17% as of today's recent price of $26.78.
THOR: 29.30 (-0.50)
